Matthew D. Montierth

Matthew D. Montierth

Auto-generated profile, based on publicly available information

Matthew D. Montierth

The University of Texas MD Anderson Cancer Center

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2022 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
SCShaolong Cao
Shaolong Cao
JWJennifer R. Wang
Jennifer R. Wang
SJShuangxi Ji
Shuangxi Ji
PYPeng Yang
Peng Yang
YDYaoyi Dai
Yaoyi Dai
WWWenyi Wang
Wenyi Wang
Single-cell RNA sequencing studies have suggested that total mRNA content correlates with tumor phenotypes. Technical and analytical challenges, however, have so far impeded at-scale pan-cancer examination of total mRNA content. Here we present a method to quantify tumor-specific total mRNA expression (TmS) from bulk sequencing data, taking into account tumor transcript proportion, purity and ploidy, which are estimated through transcriptomic/genomic deconvolution. We estimate and validate TmS in 6,590 patient tumors across 15 cancer types, identifying significant inter-tumor variability. Across cancers, high TmS is associated with increased risk of disease progression and death. TmS is influenced by cancer-specific patterns of gene alteration and intra-tumor genetic heterogeneity as well as by pan-cancer trends in metabolic dysregulation. Taken together, our results indicate that measuring cell-type-specific total mRNA expression in tumor cells predicts tumor phenotypes and clinical outcomes.

1 August 2022 in JCO Precision Oncology
Verified
Journal Article
Open access
JWJennifer Rui Wang
Jennifer Rui Wang
MMMatthew Montierth
Matthew Montierth
LXLi Xu
Li Xu
MGMaitrayee Goswami
Maitrayee Goswami
XZXiao Zhao
Xiao Zhao
MCMaria E. Cabanillas
Maria E. Cabanillas
PURPOSE: Anaplastic thyroid carcinoma (ATC) uniformly present with aggressive disease, but the mutational landscape of tumors varies. We aimed to determine whether tumor mutations affect survival outcomes in ATC. MATERIALS AND METHODS: Patients who underwent mutation sequencing using targeted gene panels between 2005 and 2019 at a tertiary referral center were included. Associations between mutation status and survival outcomes were assessed using Cox proportional hazards models. RESULTS: A total of 202 patients were included, where 122 died of ATC (60%). The median follow-up was 31 months (interquartile range, 18-45 months). The most common mutations were in TP53 (59%), BRAF (41%), TERT promoter (37%), and the RAS gene family (22%). Clinicopathologic characteristics and overall survival (OS) significantly correlated with mutations in BRAFV600E and RAS, which were mutually exclusive. The BRAFV600E mutation was associated with the presence of a papillary thyroid carcinoma precursor and significantly better OS (median OS: 24 months). RAS-mutated patients more commonly presented without cervical lymph node involvement but had the worst OS (median OS: 6 months). Tumors that were wild-type for both BRAF and RAS were enriched for NF1 mutations and harbored intermediate prognosis (median OS: 15 months). In multivariate analyses, RAS mutations were associated with a more than 2.5-fold higher risk of death (adjusted hazard ratio, 2.64; 95% CI, 1.66 to 4.20) compared with BRAFV600E. In patients treated with BRAF-directed therapy (n = 60), disease progression occurred in 48% of patients (n = 29). The median progression-free survival was 14 months. The presence of a TP53 mutation was independently associated with reduced progression-free survival in BRAFV600E-mutated patients treated with BRAF-directed therapy (adjusted hazard ratio, 2.89; 95% CI, 1.35 to 6.21). CONCLUSION: Mutation analysis provides prognostic information in ATC and should be incorporated into routine clinical care.

22 January 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DJDeborah Johnson
Deborah Johnson
KRKaylia M. Reynolds
Kaylia M. Reynolds
BPBrian Poole
Brian Poole
MMMatthew D. Montierth
Matthew D. Montierth
VTVera M. Todd
Vera M. Todd
MDMary Davis
Mary Davis
Patients with autoimmune disorders (AD) have altered cancer risks compared to the general population. Systemic lupus erythematosus and multiple sclerosis lead to a heightened risk for hematological malignancies and decreased risk for breast, ovarian, and prostate malignancies. Often patients with autoimmune disease have dysregulated antiviral immune responses, including against oncogenic viruses. To uncover the relationship between viral incidence and cancer risk in the context of autoimmune disease, we extracted electronic health records (EHR) from Vanderbilt University. ICD-9/10 codes and laboratory values were collected for hematological, lung, anal-vaginal, thyroid, hepatobiliary, bladder, prostate, and breast cancers; and viruses including Epstein Barr virus (EBV), Human papilloma virus (HPV), and Hepatitis A/B/C (Hep). Only viral infections that led to a physician visit or laboratory test were entered into the EMR; therefore, only clinically relevant cases were noted and considered positive in this study. The relationship between virus infection and cancer in an SLE cohort (SLE-cases n = 2,313, and SLE-controls n = 5,702) and an MS cohort (MS-case n = 7,277, MS-control n = 7,277) was examined by multilinear logistic regression. Viral infection was strongly associated with increased risk for cancer overall. SLE and MS patients were more susceptible to all viral infections. MS patients trended toward increased risk for cancers overall, while decreased risk for hormone-based cancers in SLE patients non-significantly reduced their risk for overall cancer. Both SLE and MS patients had increased clinically relevant EBV infection, which was associated with risk for hematological cancers. Preventing viral infections by vaccination may be especially helpful in controlling risk for cancer in SLE and MS patients.

2 October 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
SCShaolong Cao
Shaolong Cao
JWJennifer R. Wang
Jennifer R. Wang
SJShuangxi Ji
Shuangxi Ji
PYPeng Yang
Peng Yang
MMMatthew D. Montierth
Matthew D. Montierth
WWWenyi Wang
Wenyi Wang
Cancers can vary greatly in their transcriptomes. In contrast to alterations in specific genes or pathways, differences in tumor cell total mRNA content have not been comprehensively assessed. Technical and analytical challenges have impeded examination of total mRNA expression at scale across cancers. To address this, we developed a model for quantifying tumor-specific total mRNA expression (TmS) from bulk sequencing data, which performs transcriptomic deconvolution while adjusting for mixed genomes. We used single-cell RNA sequencing data to demonstrate total mRNA expression as a feature of tumor phenotype. We estimated and validated TmS in 5,015 patients across 15 cancer types identifying significant inter-individual variability. At a pan-cancer level, high TmS is associated with increased risk of disease progression and death. Cancer type-specific patterns of genetic alterations, intra-tumor genetic heterogeneity, as well as pan-cancer trends in metabolic dysregulation and hypoxia contribute to TmS. Taken together, our results suggest that measuring cell-type specific total mRNA expression offers a broader perspective of tracking cancer transcriptomes, which has important biological and clinical implications.

6 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
YJYujie Jiang
Yujie Jiang
MMMatthew D Montierth
Matthew D Montierth
KYKaixian Yu
Kaixian Yu
SJShuangxi Ji
Shuangxi Ji
SGShuai Guo
Shuai Guo
WWWenyi Wang
Wenyi Wang
Intra-tumor heterogeneity is characterized by a diverse population of tumor clones and subclones which are important drivers of tumor evolution and therapeutic response. However, accurate subclonal reconstruction at scale remains challenging. We developed a machine learning tool, CliPP, and surveyed 9,972 tumors from 32 cancer types. We found that high subclonal mutation load (sML), the fraction of subclonal single nucleotide variants (SNVs) to all SNVs in the coding region, was prognostic of survival (progression free survival or overall survival) in 18 cancer types. In 14 cancers with low to moderate tumor mutation burden (TMB), high sML was associated with better prognosis. In immunotherapy trials for 42 metastatic prostate cancer (mCRPC), high sML was predictive of favorable response to ipilimumab and associated with increased CD8 + T-cell infiltration and decreased macrophage population. A validation using 613 whole-genomes of esophageal adenocarcinoma confirms the favorable effect of high sML and the observed tumor-associated macrophage. Our study identifies sML as a key feature of cancer, suggesting a biphasic relationship between evolutionary dynamics and differential immune environments. Finally, sML may serve as an orthogonal approach to identify likely responders of immune checkpoint blockade in low to moderate TMB tumors.

2 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
YJYujie Jiang
Yujie Jiang
MMMatthew D Montierth
Matthew D Montierth
YDYu Ding
Yu Ding
KYKaixian Yu
Kaixian Yu
QTQuang Tran
Quang Tran
WWWenyi Wang
Wenyi Wang
Background: Characterizing intratumor heterogeneity and subclonal architecture from bulk DNA sequencing provides important insights into cancer evolution. However, existing subclonal reconstruction methods remain computationally demanding, hindering iterative quality control and reproducible application across large genomic cohorts. Methods: Distinct from existing likelihood-based and Bayesian approaches, we developed CliPP (Clonal structure identification through Pairwise Penalization), utilizing machine learning to add pairwise fusion penalty to the full likelihood, in order to simultaneously estimate mutation cellular prevalence and fuse compatible estimates into clusters without prespecifying the number of clusters. We benchmarked CliPP in three simulation datasets comprising 5,256 tumors for accuracy, and further evaluated its concordance with consensus calls in 2,008 tumors profiled by whole-genome sequencing from the Pan-Cancer Analysis of Whole Genomes (PCAWG) study. We then applied a standardized, quality-controlled workflow to whole-exome sequencing data from The Cancer Genome Atlas (TCGA), yielding a high-confidence cohort of 5,424 tumors across 31 cancer types. Within this cohort, we mapped the clonality of 13,960 high-confidence driver mutations in 4,375 tumors. Results: CliPP showed competitive performance across all datasets, as compared to PhylogicNDT and PyClone-VI, while gaining significant improvement in speed. In PCAWG, CliPP achieved a concordance correlation coefficient (CCC) of 0.93 with the published consensus, leading to a 96.3% agreement in driver-level clonal/subclonal assignments from the PCAWG study (Cohen’s κ = 0.81). It took approximately one hour for CliPP to complete the analysis of the entire PCAWG and TCGA cohorts, gaining noticeable time over existing methods. Applying CliPP to the TCGA cohort, we generate a complete annotation of driver clonality across TCGA samples, and observe broad patterns of driver timing that recapitulate known biology. The CliPP-on-Web app allows non-computational researchers to directly obtain subclonal annotations of their tumor samples. Conclusions: Machine learning assisted CliPP combines competitive reconstruction accuracy, substantial computational efficiency, and standardized quality control to enable reproducible subclonal reconstruction at large scale. Its pan-cancer application characterizes context-dependent patterns of driver clonality, and its software web interface enables cancer evolution inquiries from the cancer research community.